Claims:

1. An isolated monoclonal antibody, or antigen binding portion thereof, which binds human Lymphocyte-activation gene 3 (LAG-3), wherein the antibody comprises a heavy chain variable region sequence having at least 95% amino acid sequence identity to SEQ ID NO: 37 and a light chain variable region sequence having at least 95% amino acid sequence identity to SEQ ID NO: 43.

2. The antibody, or antigen binding portion thereof, of claim 1, comprising a heavy chain variable region sequence having at least 98% amino acid sequence identity to SEQ ID NO: 37 and a light chain variable region sequence having at least 98% amino acid sequence identity to SEQ ID NO: 43.

3. The antibody, or antigen binding portion thereof, of claim 1, comprising heavy and light chain variable region sequences as set forth in SEQ ID NO: 37 and SEQ ID NO: 43, respectively.

4. The antibody, or antigen binding portion thereof, of any one of the preceding claims, which inhibits binding of LAG-3 to major histocompatibility (MHC) class II molecules.

5. The antibody, or antigen-binding portion thereof, of any one of the preceding claims, which stimulates an antigen-specific T-cell response.

6. The antibody, or antigen-binding portion thereof, of claim 5, wherein the antibody stimulates interleukin-2 production by the antigen-specific T-cell.

7. The antibody, or antigen-binding portion thereof, of any one of the preceding claims, which binds to human LAG-3 protein with a K_D of 1×10^{-9} M or less.

8. The antibody, or antigen-binding portion thereof, of any one of the preceding claims, which binds to human LAG-3 protein with a K_D of 5×10^{-10} M or less.

9. A composition comprising the antibody, or antigen-binding portion thereof, of any one of the preceding claims, and a pharmaceutically acceptable carrier.

10. The composition of claim 9, further comprising at least one additional immunostimulatory antibody.

11. The composition of claim 10, wherein the immunostimulatory antibody is an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody.

12. The composition of claim 10, wherein the immunostimulatory antibody is an anti-PD-1 antibody.

13. An immunoconjugate comprising the antibody, or antigen-binding portion thereof, of any one of claims 1 to 8, linked to a therapeutic agent.

14. An isolated nucleic acid molecule encoding the antibody, or antigen-binding portion thereof, of any one of claims 1 to 8.

15. An expression vector comprising the nucleic acid molecule of claim 14.

16. A host cell comprising the expression vector of claim 15.

17. A method for preparing an anti-LAG-3 antibody which comprises expressing the antibody in the host cell of claim 16 and isolating the antibody from the host cell.

18. The antibody, or antigen binding portion thereof, of any one of claims 1 to 7, or the composition of any one of claims 9 to 12, for use in therapy.

19. The antibody, or antigen binding portion thereof, of any one of claims 1 to 8, and at least one additional immunostimulatory antibody, for use in therapy.

20. The antibody, or antigen binding portion thereof, and the at least one additional immunostimulatory antibody, of claim 19 for the use of claim 19, wherein the

immunostimulatory antibody is an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody.

21. The antibody, or antigen binding portion thereof, and the at least one additional immunostimulatory antibody, of claim 19 for the use of claim 19, wherein the immunostimulatory antibody is an anti-PD-1 antibody.

22. The antibody, or antigen binding portion thereof, and at least one additional immunostimulatory antibody, of any one of claims 19-21 for the use of any one of claims 19-21, wherein the antibody, or antigen binding portion thereof, and the at least one additional immunostimulatory antibody are to be administered concurrently, separately or sequentially.

23. The antibody, or antigen-binding portion thereof, of any one of claims 1 to 8, or the composition of any one of claims 9 to 12, for use in stimulating an antigen-specific T cell response.

24. The antibody, or antigen-binding portion thereof, of any one of claims 1 to 8, or the composition of any one of claims 9 to 12, for use in stimulating an immune response in a subject.

25. The antibody, or antigen-binding portion thereof, of any one of claims 1 to 8, or the composition of any one of claims 9 to 12, for use in inhibiting growth of tumor cells in a subject.

26. The antibody, or antigen-binding portion thereof, of any one of claims 1 to 8, or the composition of any one of claims 9 to 12, for use in treating viral infection in a subject.